Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study

Effect of Tocilizumab in Hospitalized Patients with Severe COVID-19 Pneumonia: A Case-Control Cohort Study

Tocilizumab, an anti-interleukin-6 receptor, administrated during the right timeframe may be beneficial against coronavirus-disease-2019 (COVID-19) pneumonia. All patients admitted for severe COVID-19 pneumonia (SpO2 ≤ 96% despite O2-support ≥ 6 L/min) without invasive mechanical ventilation were in...

Full description

Bibliographic Details
Main Authors: Benjamin Rossi, Lee S. Nguyen, Philippe Zimmermann, Faiza Boucenna, Louis Dubret, Louise Baucher, Helene Guillot, Marie-Anne Bouldouyre, Yves Allenbach, Joe-Elie Salem, Paul Barsoum, Arezki Oufella, Helene Gros
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Pharmaceuticals
Subjects:
anti-interleukin-6
COVID-19
SARS CoV2
severe pneumonia
cytokine release syndrome
Online Access:https://www.mdpi.com/1424-8247/13/10/317

Internet

https://www.mdpi.com/1424-8247/13/10/317

Similar Items